AZN Stock Analysis: AstraZeneca | ST
Drug Manufacturers - General | ST, Sweden | Market Cap: 2.408.526m SEK | 12M Return: 4.4% | GB0009895292 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.09B
EPS Trend: 96.9%
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AstraZeneca PLC is a UK-based biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. As a mega-cap firm in the global pharmaceuticals sector, its business model is centered on proprietary drug development, where long R&D timelines and patent protections on novel therapies drive the majority of revenue.
The companys product portfolio spans several major therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Flagship products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, and Farxiga/Forxiga, alongside a broader range of oncology, respiratory, and rare disease treatments such as Ultomiris, Soliris, and Strensiq.
AstraZeneca distributes its products globally through local representative offices and third-party distributors, reaching primary and specialty care physicians across the UK, the Americas, Europe, Asia, Africa, and Australasia. The company maintains several strategic partnerships to expand its pipeline, including agreements with Tempus and Pathos for an oncology-focused multimodal AI foundation model, CSPC Pharmaceutical Group for novel oral drug candidates, and Nucs AI Inc. for AI-driven response prediction in radioconjugates.
The company was incorporated in 1992 and is headquartered in Cambridge, UK. It was formerly known as Zeneca Group PLC before adopting the AstraZeneca name in April 1999.
- Tagrisso and Imfinzi fuel oncology segment revenue growth
- Rare disease unit margins expand post Alexion integration
- China volume-based procurement pressures emerging market pricing
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.83 > 1.0 |
| NWC/Revenue: -5.90% < 20% (prev -8.14%; Δ 2.23% < -1%) |
| CFO/TA 0.12 > 3% & CFO 13.8b > Net Income 10.4b |
| Net Debt (30.3b) to EBITDA (20.5b): 1.48 < 3 |
| Current Ratio: 0.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.56b) vs 12m ago 0.06% < -2% |
| Gross Margin: 81.77% > 18% (prev 81.38%; Δ 0.39% > 0.5%) |
| Asset Turnover: 53.50% > 50% (prev 50.26%; Δ 3.24% > 0%) |
| Interest Coverage Ratio: 8.09 > 6 (EBIT TTM 14.1b / Interest Expense TTM 1.74b) |
| A: -0.03 (Total Current Assets 28.2b - Total Current Liabilities 31.8b) / Total Assets 117b |
| B: 0.11 (Retained Earnings 12.7b / Total Assets 117b) |
| C: 0.12 (EBIT TTM 14.1b / Avg Total Assets 115b) |
| D: 0.77 (Book Value of Equity 50.7b / Total Liabilities 66.0b) |
| Altman-Z'' = 1.79 = BBB |
| DSRI: 1.05 (Receivables 16.1b/14.2b, Revenue 61.3b/56.5b) |
| GMI: 1.00 (GM 81.38% / 81.77%) |
| AQI: 0.99 (AQ_t 0.62 / AQ_t-1 0.62) |
| SGI: 1.09 (Revenue 61.3b / 56.5b) |
| TATA: -0.03 (NI 10.4b - CFO 13.8b) / TA 117b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of August 25, 2026, the stock is trading at SEK 1568.00 with a total of 370,188 shares traded. Over the past week, the price has changed by +5.31%, over one month by -4.33%, over three months by -10.56% and over the past year by +4.35%.
Current recommended Stop Loss: 1513.70 (which is 3.5% or 1.3 ATR below the current price).
AstraZeneca has no consensus analysts rating.
Market Cap USD = 254b (2409b SEK * 0.1056 SEK.USD)
P/E Trailing = 24.4336
P/E Forward = 15.674
P/S = 39.2485
P/B = 4.9534
P/EG = 1.3869
Revenue TTM = 61.3b USD
EBIT TTM = 14.1b USD
EBITDA TTM = 20.5b USD
Long Term Debt = 23.7b USD (from longTermDebt, last quarter)
Short Term Debt = 6.29b USD (from shortTermDebt, last quarter)
Debt = 35.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.75b
Net Debt = 30.3b USD (calculated: Debt 35.3b - CCE 5.01b)
Enterprise Value = 285b USD (254b + Debt 35.3b - CCE 5.01b)
Interest Coverage Ratio = 8.09 (Ebit TTM 14.1b / Interest Expense TTM 1.74b)
EV/FCF = 30.02x (Enterprise Value 285b / FCF TTM 9.48b)
FCF Yield = 3.33% (FCF TTM 9.48b / Enterprise Value 285b)
FCF Margin = 15.46% (FCF TTM 9.48b / Revenue TTM 61.3b)
Net Margin = 17.02% (Net Income TTM 10.4b / Revenue TTM 61.3b)
Gross Margin = 81.77% ((Revenue TTM 61.3b - Cost of Revenue TTM 11.2b) / Revenue TTM)
Gross Margin QoQ = 83.56% (prev 82.48%)
Tobins Q-Ratio = 2.44 (Enterprise Value 285b / Total Assets 117b)
Interest Expense / Debt = 4.95% (Interest Expense 1.74b / Debt 35.3b)
Taxrate = 16.95% (2.13b / 12.6b)
NOPAT = 11.7b (EBIT 14.1b * (1 - 16.95%))
Current Ratio = 0.89 (Total Current Assets 28.2b / Total Current Liabilities 31.8b)
Debt / Equity = 0.70 (Debt 35.3b / totalStockholderEquity, last quarter 50.7b)
Debt / EBITDA = 1.48 (Net Debt 30.3b / EBITDA 20.5b)
Debt / FCF = 3.19 (Net Debt 30.3b / FCF TTM 9.48b)
Total Stockholder Equity = 48.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.11% (Net Income 10.4b / Total Assets 117b)
RoE = 21.68% (Net Income TTM 10.4b / Total Stockholder Equity 48.2b)
RoCE = 19.65% (EBIT 14.1b / Capital Employed (Equity 48.2b + L.T.Debt 23.7b))
RoIC = 13.29% (NOPAT 11.7b / Invested Capital 88.2b)
WACC = 5.08% (E(254b)/V(290b) * Re(5.22%) + D(35.3b)/V(290b) * Rd(4.95%) * (1-Tc(0.17)))
Discount Rate = 5.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.90 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈8.96b ; Y1≈10.3b ; Y5≈15.1b
[DCF] Fair Price = 127.2 (EV 228b - Net Debt 30.3b = Equity 197b / Shares 1.55b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.93 | EPS CAGR: 12.94% | SUE: 1.53 | # QB: 1
Revenue Correlation: 98.99 | Revenue CAGR: 12.66% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.69 | Chg30d=+0.56% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=10.45 | Chg30d=+0.64% | Revisions=+0% | GrowthEPS=+14.1% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=11.39 | Chg30d=+0.44% | Revisions=+0% | GrowthEPS=+9.0% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: -12% (up=2, down=3)